and his genetically oriented colleagues in 1Thi#{246}#{227}I medicine and biochemistry now believe that all inherited metabolic variations arise from alterations in the biochemical composition of the organism; it is assumed that these alterations are the direct result of variations in the gene or genes which determine the synthesis of a specific protein molecule. Some well-known hereditary metabolic disorders, such as phenylketonuria and alcaptonuria, have been shown to be inherited as simple recessives, with the fundamental enzyme defect attributable to the lack or alteration of a single gene at a single locus. There are other metabolic diseases, however, in which the mode of inheritance is probably more complex. Here, a particular biochemical phenotype may be either under the combined genetic influence of seevral distinct genes, or controlled by one gene at any of several loci.
Because of the increasing clinical interest in the metabolic aspects of diseases, it is becoming more important for the clinical chemist to be aware of some of the problems associated with the diagnosis of hereditary diseases. This report will be primarily concerned with the significance and interpretation of variations in the urinary excre- Urine samples from seizure patients were referred to our laboratory by Dr. Richard J. Allen of the Department of Pediatrics and Communicable Diseases, University of Michigan Medical School; other samples were referred by members of the same department.
Submitted for publication May 17, 1961.
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tion of phenolic acids, aipha-keto acids, and indolic acids which are known to be associated with some inherited metabolic disorders, in addition to those of less certain genetic status.
Phenolic Acids
In our laboratory, two-dimensional paper chromatograms of urine extracts were prepared according to the procedure of Armstrong et at. (1) , and developed with diazotized sulfanilic acid, diazotize#{149}d p-nitroaniline, or 2,6-dichioroquinone chlorimide. This technic was found satisfactory for the qualitative assay of phenolic acids in urine.
Phenylketonuria
The most outstanding hydroxy metabolite of phenylalanine found in the urine of phenylketonurics is o-hydroxyphenylacetic acid (o-HPAA). Fig. 1 show how this is possible.
Because of the block in p-hydroxylation, phenylalanine is transaminated or oxidatively deaminated to phenylpyruvic acid, which is then subjected to hydroxylation.
Although hydroxylation of phenylpyruvic acid in the meta or para positions is possible, it appears that orthohydroxylation is favored and that the o-hydroxyphenylpyruvic acid so formed is subsequently decarboxylated to o-HPAA.
An alternate pathway to o-tyrosine is also possible, but there is no evidence, as yet, that this pathway is operating in phenylketonuria.
When monamine oxidase inhibitors have been administered to phenylketonurics, there is an increased excretion of phenylethylamine but not o-tyramine (4). If o-tyrosine was being formed in increased amounts, we would also expect an increased excretion of o-tyramine.
A rapid and accurate test for the presence of o-HPAA would be to run the urine on a one-dimensional paper chromatogram in iopropanol-ammonia-water (8:1 :1) and develop with 2,6-dichioroquinone chiorimide or diazotized sulfanilic acid (5) . Figure 4 shows such a chromatogram of phenylketonuric whole urine on the first through the thirteenth day of a phenylalanine-free diet. The rapidly migrating o-HPAA spot can be easily qualified in a 4-to 5-hour run. In no other metabolic disease has o-HPAA been found to be excreted in increased amounts.
p-Hydroxyphenylpyruvic acid, p-hydroxyphenyllactic acid, and phydroxyphenylacetic acid have been reported to be excreted in somewhat increased amounts in phenylketonuria (6, 7) . If this is true, however, it seems more likely that this tryosyluria reflects a liver enzyme dysfunction (inhibition of p-hydroxyphenylpyruvie acid oxidase?) rather than a direct anomaly of phenylalanine metabolism (8,9).
Although whole urine may be used, ethyl acetate extracts of acidified urine are more reliable.
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Galactosemia
The analysis in our laboratory of the urine of an untreated, 1-month old patient with galactosemia revealed a greatly increased excretion of p-hydroxyphenylpyruvic acid and p-hydroxyphenyllactic acid. This abnormal pattern is shown in Fig. 5A . On a galactosefree diet, these metabolites completely disappeared. As in phenylketonuria, the increased excretion of these compounds in all probability reflects the marked liver dysfunction and associated enzyme alteration encountered with this disease.
Infantile Tyrosinosis
Premature, or very young infants, occasionally exhibit a tyrosinura which invariably returns to normal (10, 11) . Figure SB represents just such a condition.
The patient was a 2-week old male with a diagnosis of hypoglycemia, jaundice, and convulsions. The chromatographic pattern is much the same as that of the galactosemic patient just discussed, with increased excertion ef p-hydroxyphenylpyruvic acid and its derivatives. In addition, this patient excreted increased amounts of tyrosine.
The abnormally increased concentrations of all these metabolites, however, returned to normal some 2 months later.
None of the 3 abnormally increased spots which appear to be common to these two chromatograms ( Fig. 5A and 5B) has been identified. The lower spot appears to be spot 34 of Armstrong et at.
(1) and the other 2 are arbitrarily designated as spots 44 and 45. The increased excretion of tyrosine and p-hydroxyphenyllactic acid in a nonscorbutic individual presumably without liver damage has been reported in only one case (12) . A genetic basis for this condition is therefore doubtful, and the tyrosinosis probably reflects some acquired alteration of tyrosine metabolism. It would not be surprising to find a similar biochemical picture in other hereditary or acquired diseases involving disorders of the liver.
Convulsive Disorders
Three cases of altered urinary phenolic acid patterns have come to our attention in the course of a survey of children with convulsive disorders.
One case was an 18-month-old girl with myoclonic seizures and mental retardation.
There were no siblings, but a maternal granduncle who began to have seizures at the age of 13 was placed in a state institution in his late twenties and died shortly thereafter.
The phenolic acid chromatogram ( Fig. 6A ) of the propositus revealed an abnormal compound which migrated to a position which has not been previously reported.
This substance may be the result of drug therapy (possibly Celontin, 150 mg. twice daily); the known hydroxylated products of the other administered drugs (Dilantin and phenobarbital) migrate to different positions. This spot will be designated as spot 46.
In the other two patients, 7-and 18-month-old girls with myoclonic seizures and mental retardation, an interesting alteration in phenolic acid excretion was encountered.
This consisted in the greatly increased excretion, in both cases, of p-hydroxyphenylpropionic acid (Fig. 6B) . Although no members of their immediate families were similarly affected, both families did have some history of central nervous system disorders.
In one pedigree, a paternal uncle and paternal granduncle had childhood convulsions.
In the other pedigree, one sibling died of an unknown central nervous system disorder at 10 months, a paternal aunt had seizures as a child, and a paternal greataunt had grand-mal epilepsy.
The increased excretion of phydroxyphenylpropionic acid was found in every urine sample examined over a 5-month period for one patient and in a high percentage of the urine samples of the other. The amount of p-hydroxyphenylpropionic acid also seemed to be closely correlated with the amount of p-hydroxyphenylacetic acid excreted, and although the intensities of these spots varied, their relative color intensities remained constant.
The patient who excreted p-hydroxyphenylpropionic acid most persistently also seemed to excrete less than normal amounts of the 3-methoxy-4-hydroxy substituted phenyihydracrylic, mandelic, and cinnamic acids.
In view of the evidence that p-hydroxyphenyllactic acid can serve as a precursor of p-hydroxyphenylpropionic acid through p-hydroxycinnamic (p-coumaric) acid in the rat (13), it is possible that phydroxyphenyipropionic acid is formed by a similar pathway in man. However, since p-hydroxyphenylpropionic acid is not normally excreted in man, it appears that this compound is efficiently metabolized under normal conditions. Therefore, in order to explain the observed increased excretion of p-hydroxyphenylpropionic acid in the cases described, we could postulate some block in the dehydrogenation of p-hydroxyphenylpropionic acid to p-hydroxycinnamic acid. The decreased excretion of the 3-methoxy derivatives of p-hydroxycinnamic acid might then result from the increased concentration of p-
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hydroxyphenylpropionic acid secondarily inhibiting the O-methylation of p-hydroxycinnamic acid. A proposed scheme for the metabolism of these tyrosine derivatives is outlined in Fig. 7 . However, because our knowledge of the intermediary metabolism of phenolic acids is still fragmentary, in addition to the fact that these variations could arise as secondary effects, one must be cautious in relating these abnormally excreted metabolites to a specific clinical state. It is interesting that other convulsive patients of equal size and weight receiving the same dose of phenobarbital may not show p-hydroxyphenobarbital on their chromatograms. It is possible that variation in the metabolism of this drug may in itself be under genetic control. In this respect, succinylcholine (14) and isoniazid (15) are two compounds which have been shown to be metabolized differently in individuals of different genetic constitutions.
Since it is likely that other drugs could be similarly excreted, it is imperative that drug therapy be stopped or strictly regulated before an unknown spot can be ascribed to an endogenous origin. In addition, the intake of such substances as aspirin, coffee, bananas, and vanilla must be carefully controlled as they are known to alter phenolic or indolic acid patterns significantly (16) (17) (18) (19) ).
x-Keto Acids
Phenylketonuria
In this disease, phenylpyruvic acid is usually excreted at the rate of 0.3-2.0 gm./24 hours, and in this range of concentration can be readily detected by the standard ferric chloride reaction.
However, it is possible to get a negative ferric chloride reaction with phenyl- Some factors which may be contributing to this negative test are the transitory nature of the reaction, the masking effect of phosphates, and the effects of light and temperature.
Therefore, in those cases of suspected phenylketonuria which give a negative ferric chloride reaction either in solution or on reagent paper strips, further testing should be instituted employing technics which would minimize the above factors.
Saifer and Harris (21) have recently developed a technic in which the ferric chloride color reaction is stabilized by low temperature, omission of light, the introduction of ferrous ions, and precipitation of the phosphates by uranyl nitrate.
The use of a mixture of magnesium chloride, ammonium chloride, and ammonia has also been shown to be effective in removing phosphates (22) . The ether extraction method of Berry and Woolf (23) is highly satisfactory for routine quantitative determinations of phenylpyruvic acid. False positive color reactions with ferric chloride can result from such urinary compounds as salicylic acid (purple), chiorpromazine derivatives (green) (24) , and bilirubin (green) (20) ; the latter can be removed from the urine by absorption with calcium carbonate. As will be seen in the discussion of the following metabolic disorder involving keto-aciduria, the increased excretion of phenylpyruvic acid alone may not always be pathognostic for phenylketonuria.
Smith-Strang Syndrome
The only other metabolic disorder in which phenylpyruvic acid has been found to be excreted in increased amounts is that described by Smith and Strang (25) and Jepson et at. (26) . The 9-month-old child they studied was mentally deficient, had completely white hair, and excreted phenylpyruvic acid, p-hydroxyphenylacetic acid, p-hydroxyphenyllactic acid, indoleacetic acid, and -hydroxybutyric acid in the urine. Phenotypically, this case might easily have been classified as phenylketonuria.
However, the fact that no o-HPAA could be detected in the urine, which as mentioned earlier is diagnostic for phenylketonuria, implicated a block in -keto acid metabolism rather than a defect in the para-hydroxylation of phenylalanine. This syndrome is a good example of a biochem4cal phenotype which is similar to that associated with phenylketonuria, but undoubtedly under the control of a separate genetic mechanism.
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Branched-Chain Ketonuria ("Maple-Syrup Urine" Disease)
In this condition, characterized by marked loss of all integrated central nervous system functions, the branched-chain -keto acids (riketoisovaleric, -ketoisocaproic, rz-keto-$-methyl-n-valeric) and probably their -hydroxy acids are excreted in the urine in increased amounts (27, 28) . The disease appears to be related to the block in the metabolism (decarboxylation?) of the ct-keto acids encountered in the Smith-Strang disease described above. In one 20-month-old patient examined by Dancis et at. (27) , -ketoisocaproic acid andketoisovaleric acid were found to be excreted at the rate of about 250 mg./24 hours.
Although the branched-chain cc-keto acids give a different color reaction with ferric chloride (blue-black) than does phenylpyruvic acid (blue-green), some confusion in the qualitative interpretation of the keto acids could result. Because of this factor, in addition to the relative instability of ra-keto acids, it would seem best to convert them to their 2,4-dinitrophenylhydrazones and examine them chromatographically.
For this purpose, the Menkes modification Alterations of Less Certain Status Menkes (29) has reported two children with severe cerebral dysfunction who possessed abnormal excretion patterns of c-keto acids. One had greatly increased amounts of -ketoglutaric acid (320 mg./sq. meter/24 hours) and the other showed the presence of 2 abnormally increased -keto acids, which were not indentified.
Indolic Acids
The intermediary metabolism of tryptophan appears to be especially sensitive to metabolic disturbances which are not primarily related to tryptophan metabolism. In all of the diseases which have been discussed here there is generally an increased urinary excretion of indoleacetic acid, indolelactic acid, and indican, and decreased excretion of 5-hydroxyindoleacetic acid. It has been suggested that perhaps these alterations in indole excretion may be due in part to an inhibition of tryptophan or 5-hydroxytryptophan decarboxylase brought about by the increased production of abnormal metabolites associated with these disorders (32) . That these alterations in tryptophan metabolism represent separate mechanisms has been (top) Two-dimensional chromatogram of urinary phenolic acids from a phenylketonuric patient. Note increased excretion of o-hydroxyphenylacetic acid (13) and phydroxyphenyllactic acid (14) . largely discounted by the fact that dietary control of the abnormally increased primary metabolite results in the normal excretion of indoles (33, 34) . Indoleacetic acid has been demonstrated to be excreted in increased amounts in alkaline urine (33) . However, it does not seem likely, in view of the acid urines found in ketoacidurias, that urinary pH would be an important contributing factor to the increased excretion of indoleacetic acid. Moreover, only indoleacetic acid excretion would be exected to be affected in this manner, as the polar effect of hydroxyl substitution of the 5-hydroxyindoleactic acid and indoleacetic acid molecules would probably make these compounds less likely to be affected by urinary pH (34) .
It is of interest that the oral administration of indoleacetic acid and certain phenylalanine metabolites in man can result in an increased excretion of 5-hydroxyindoleacetic acid (30, 35) . These experimental conditions, however, may result from the short-term release of tissue serotonin and its subsequent oxidation to 5-hydroxyindoleacetic acid, in which case an attempt should not be made to relate these findings to the chronic clinical state.
Which of these above-mentioned alterations in the excretion of indoles can be attributed to metabolic variation and which to renal factors (36), has not been fully resolved.
Hartnup Disease
This metabolic disorder (37) appears to be one inherited disease in which the primary error may involve tryptophan directly, either through altered transport (38) +, slight to moderately increased excretion; and ++, moderate to greatly increased excretion.
other disorders discussed throughout this presentation, the following conclusions might be drawn:
1. Phenylketonuria can be readily separated from the other ketoacidurias by the presence of increased amounts of o-hydroxyphenylacetic acid.
2. The increased excretion of -ketoisocaproic acid and rz-ketoisovaleric acid should be definitive for branched-chain ketonuria. 3. Secondary disturbances in tyrosine and tryptophan metabo.. lism, which are associated with many of these disorders, are often expressed in an increased production of the tyrosine metabolite p-hydroxyphenylpyruvic acid and its derivatives (which appear to be characteristic of liver dysfunction in both hereditary and acquired diseases) and in an increased excretion of the tryptophan metabolites of indoleacetic acid, indolelactic acid, and indican, and a decreased excretion of 5-hydroxyindoleacetic acid. 4. Because of the biochemical or symptomatic similarities between many metabolic disorders, it is sometimes difficult to make an accurate diagnosis unless variations in the excretion patterns for each disease entity are thoroughly understood, so that overlapping factors or variations in one factor will not confuse the diagnosis.
5. The dietary and drug intake of the patient under observation must be assiduously controlled before an abnormal, or abnormally increased, metabolite can be assigned an endogenous metabolic origin.
Keeping these facts and precautions in mind should reduce the likelihood of reporting a variant of a known hereditary metabolic disease as a new disorder.
Nevertheless, since the study of metabolic diseases is so new, it is important at this stage to report all significant variations of even the well-established diseases.
